TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12575211

Group type: EXPERIMENTAL
Intervention: First aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Second aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and 1 x 10(6) units of aprotinin for intravenous bolus)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amrinone combined with aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and amrinone bolus of 1 mg/kg followed by maintenance of 8 micrograms/kg.min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (equivalence without aprotinin)
Number of subjects: 32
Study: 9613383

Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution therapy (IHT) for 6 weeks with venesection and volume replacement using hydroxyethylstarch, targeting a haematocrit of 35%.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 2
Study: 7852229

Group type: EXPERIMENTAL
Intervention: Low dose intramuscular hepatitis B vaccine (2 micrograms at first, followed by 1 microgram each at 1, 2, and 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard dose intramuscular hepatitis B vaccine (10 micrograms each at 0, 1, and 6 months)
Number of subjects: 120
Study: 30902602

Group type: EXPERIMENTAL
Intervention: Listening to music during extraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extraction without music (control group)
Number of subjects: 40
Study: 28244261

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study: 25713462

Group type: EXPERIMENTAL
Intervention: Integrated neurocognitive therapy (INT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 156
Study: 22923232

Group type: EXPERIMENTAL
Intervention: HIT-1 (1 min rest between intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: HIT-3 (3 min rest between intervals)
Number of subjects: 12
Study: 20683104

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg b.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17224034

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered in the wound
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo administered in the wound
Number of subjects: 10
Study: 16167244

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (35-45 Gy within 4-5 weeks) plus preoperative chemotherapy with 5-fluorouracil followed by lower-anterior resection (Group A)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by lower-anterior resection (Group B)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection only (Group C)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (Group B and C)
Number of subjects: 157
Study: 12072716

Group type: EXPERIMENTAL
Intervention: LASIK procedure using Keratom II Coherent‐Schwind excimer laser and Moria Model One microkeratome (150-microm head)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LASIK procedure
Number of subjects: 57
Study: 10535234

Group type: EXPERIMENTAL
Intervention: Exposure-based contingency management (CM) treatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive self-control (SC) treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Education support (ES) control condition
Number of subjects: 81
Study: 8849353

Group type: EXPERIMENTAL
Intervention: Stress management group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 141
Study: 2088462

Group type: EXPERIMENTAL
Intervention: High protein diet (HP) at 200% of recommended dietary allowances (RDA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low protein diet (LP) at 100% of recommended dietary allowances (RDA)
Number of subjects: 17
Study: 7024200

Group type: EXPERIMENTAL
Intervention: Treatment group with enhanced commitment (contracts signed by participant and at least one friend, relative, or peer)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group with baseline commitment (contracts signed by participant only)
Number of subjects: 106
Study: 31569161

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) via a mobile device
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 45
Study: 31511230

Group type: EXPERIMENTAL
Intervention: H pylori treatment with amoxicillin and omeprazole for two weeks
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (C, E, and selenium) for 7.3 years
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Garlic supplementation (extract and oil) for 7.3 years
Number of subjects: 3365
Study: 28641642

Group type: EXPERIMENTAL
Intervention: Cellular immunotherapy combined with bortezomib (combined therapy group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Only chemotherapy including bortezomib (single chemotherapy as control group)
Number of subjects: 76
Study: 25528325

Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for Tdap vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for MCV4 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for HPV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-Located Vaccination Clinics (SLVCs) for influenza vaccine
Number of subjects: 0
Study: 24242195

Group type: EXPERIMENTAL
Intervention: Telehealth follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 21883103

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (home-based program supported by telephone calls)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention (three weekly supervised sessions in a fitness center)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both interventions (lifestyle and structured)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 186
Study: 19596729

Group type: EXPERIMENTAL
Intervention: Multifaceted discomfort-reducing intervention (verbal suggestions, visual focusing activity, ethyl chloride)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Office routine control group
Number of subjects: 41
Study: 18265707

Group type: EXPERIMENTAL
Intervention: Potassium oxalate gel applied prior to bonding procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Bond (3M ESPE), One‐Up Bond F (Tokuyama), and AdheSE (Ivoclar Vivadent)
Number of subjects: 0
Study: 15221991

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg) plus 5-fluorouracil/leucovorin (5-FU/LV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5-FU/LV) alone
Number of subjects: 104
Study: 12149107

Group type: EXPERIMENTAL
Intervention: 500 ml of tap water
Number of subjects: 14

Group type: COMPARATOR
Intervention: 20 ml of tap water (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Water ingestion in transplant recipients
Number of subjects: 14
Study: 10356431

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate 50 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine 2 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine 3 mg/kg
Number of subjects: 15
Study: 8134070

Group type: EXPERIMENTAL
Intervention: Educational brochures
Number of subjects: 108

Group type: COMPARATOR
Intervention: No educational brochures (Control)
Number of subjects: 108
Study: 2674067

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perioperative transfusion
Number of subjects: 0
Study: 1102383

Group type: EXPERIMENTAL
Intervention: Loesferron effervescent iron tablet
Number of subjects: 57
Study: 30799502

Group type: EXPERIMENTAL
Intervention: ibrutinib + venetoclax + obinutuzumab (IVO) with IM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVO + IM for patients without minimal residual disease complete response (MRD‐CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVO + IM discontinuation for patients with MRD‐CR
Number of subjects: 0
Study: 29233141

Group type: EXPERIMENTAL
Intervention: Internet-based neck-specific exercise programme
Number of subjects: 140

Group type: COMPARATOR
Intervention: Neck-specific exercises at a physiotherapy clinic
Number of subjects: 140
Study: 26231855

Group type: EXPERIMENTAL
Intervention: Home-visiting intervention (n=644 mothers)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Standard care (n=594 mothers)
Number of subjects: 1238
Study: 27129119

Group type: EXPERIMENTAL
Intervention: GSK2485852 420 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GSK2485852 70 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22944150

Group type: EXPERIMENTAL
Intervention: Daily interactive and personally weight-relevant text-messages
Number of subjects: 170

Group type: COMPARATOR
Intervention: Monthly e-newsletters
Number of subjects: 170
Study: 18937318

Group type: COMPARATOR
Intervention: ABMT (Autologous Bone Marrow Transplantation), n = 20
Number of subjects: 72

Group type: COMPARATOR
Intervention: 13-cis-retinoic acid (13-cis-RA), n = 23
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ABMT and 13-cis-RA, n = 6
Number of subjects: 72
Study: 17456380

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for two months
Number of subjects: 19
Study: 15824079

Group type: EXPERIMENTAL
Intervention: Antero-apical (AA) pad position
Number of subjects: 307

Group type: COMPARATOR
Intervention: Antero-posterior (AP) pad position
Number of subjects: 307
Study: 12205284

Group type: EXPERIMENTAL
Intervention: Risperidone (oral solution) at a mean dose of 1.38 mg/d (range: 0.02‐0.06 mg/kg/d) for 48 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Risperidone (previously treated group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (previously treated group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 77
Study: 9858353

Group type: EXPERIMENTAL
Intervention: Four 1-hour small group counseling sessions with a booster session at 2 months
Number of subjects: 996

Group type: COMPARATOR
Intervention: Two 20-minute individual counseling sessions
Number of subjects: 996
Study: 7618457

Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone agonist treatment (D‐Trp‐6‐LHRH depot) before hysterectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immediate hysterectomy
Number of subjects: 50
Study: 2392858

Group type: EXPERIMENTAL
Intervention: 3 X 100 mg Trapidil (Rocornal) daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Trapidil
Number of subjects: 41
Study: 344090

Group type: EXPERIMENTAL
Intervention: Trimebutine 200 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29381690

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day until progression or unacceptable toxicity
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 95
Study: 26899745

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone 500 mg every 12 hours for 3 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 500 mg every 12 hours for 7 days
Number of subjects: 71
Study: 24429901

Group type: EXPERIMENTAL
Intervention: Roxithromycin for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Azithromycin for 12 weeks
Number of subjects: 22
Study: 22633302

Group type: EXPERIMENTAL
Intervention: HeartNet Ventricular Support System
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 20552087

Group type: EXPERIMENTAL
Intervention: All-composite resin crowns
Number of subjects: 200

Group type: COMPARATOR
Intervention: All-ceramic crowns
Number of subjects: 200
Study: 18606019

Group type: EXPERIMENTAL
Intervention: True acupuncture at LI-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 20
Study: 16238908

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 40,000 U once weekly
Number of subjects: 533

Group type: COMPARATOR
Intervention: Darbepoetin alfa (DARB) 2.25 mcg/kg once weekly
Number of subjects: 533
Study: 12090862

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763
Study: 10334165

Group type: EXPERIMENTAL
Intervention: Sedation group (lidocaine spray, atropine i.m. and diazepam i.v.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsedation group (lidocaine spray and atropine sulfate i.m.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 8943447

Group type: EXPERIMENTAL
Intervention: Multiplane transesophageal echocardiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biplane transesophageal echocardiography
Number of subjects: 50
Study: 1769643

Group type: EXPERIMENTAL
Intervention: Oxilofrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6801516

Group type: EXPERIMENTAL
Intervention: High Nitrogen Vivonex
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Product MJ7041
Number of subjects: 4

Group type: COMPARATOR
Intervention: Solid food
Number of subjects: 4
Study: 31628482

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lovastatin (in subjects not using biologic therapy)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (in subjects not using biologic therapy)
Number of subjects: 64
Study: 31401683

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) plus intravitreal erythropoietin (EPO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone
Number of subjects: 34
Study: 27996199

Group type: EXPERIMENTAL
Intervention: Postoperative intermittent TAP catheters with bupivacaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Postoperative intermittent TAP catheters with saline
Number of subjects: 93
Study: 26307030

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Current and former smokers
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 1256
Study: 24520101

Group type: EXPERIMENTAL
Intervention: Plasma procalcitonin levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in idiopathic scoliosis patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in neuromuscular scoliosis patients
Number of subjects: 50
Study: 22313792

Group type: EXPERIMENTAL
Intervention: Desmopressin plus oxybutynin (5 mg)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Desmopressin plus placebo
Number of subjects: 206
Study: 18834819

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study: 17767476

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/day) + Proton Pump Inhibitor (PPI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (PPI) alone
Number of subjects: 62
Study: 14695387

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 27
Study: 12231497

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mandibular Repositioning Splint (MRS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CPAP in patients with mild SAHS (AHI < 15, n = 18)
Number of subjects: 48
Study: 9682109

Group type: EXPERIMENTAL
Intervention: In situ alignment group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (routine refraction)
Number of subjects: 71
Study: 8131704

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal controls (22 healthy volunteers)
Number of subjects: 31
Study: 3419597

Group type: EXPERIMENTAL
Intervention: Levodopa (suprathreshold rates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levodopa (threshold rates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levodopa (subthreshold rates)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31077093

Group type: EXPERIMENTAL
Intervention: Lecture plus Case‐based Learning (CBL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lecture only (Control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lecture plus CBL
Number of subjects: 140
Study: 31118278

Group type: EXPERIMENTAL
Intervention: 25-gauge pencil point spinal needles
Number of subjects: 140

Group type: COMPARATOR
Intervention: 27-gauge pencil point spinal needles
Number of subjects: 140
Study: 28869006

Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg for first 4 weeks, titrated up to 800 mg for remaining 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (two matching capsules for first 4 weeks, titrated to four matching capsules for remaining 8 weeks)
Number of subjects: 68
Study: 24816997

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in multiple daily insulin patients
Number of subjects: 20
Study: 24050845

Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: NDS group
Number of subjects: 48
Study: 17144387

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study: 12680744

Group type: EXPERIMENTAL
Intervention: Procyclidine (15 mg, oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10100062

Group type: EXPERIMENTAL
Intervention: Glucose ingestion in hypertensive patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Post-glucose load plasma insulin in hypertensive patients with microalbuminuria (n = 14)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Systolic BP quartile analysis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including plasma insulin, systolic and diastolic BP, plasma glucose, triglycerides, and body mass index
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia in hypertensive and normotensive atherosclerotic patients
Number of subjects: 85
Study: 8669993

Group type: COMPARATOR
Intervention: Knee immobilization (I)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half-inch shoe-lift (I1/2")
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: One-inch shoe-lift (I1")
Number of subjects: 10
Study: 1802019

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.5 mg/m2/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.0 mg/m2/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.25 mg/m2/day
Number of subjects: 16
Study: 6305183

Group type: COMPARATOR
Intervention: Soya pulp A (39% dietary fiber)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Purified soya fiber B (79% dietary fiber)
Number of subjects: 6
Study: 31429205

Group type: EXPERIMENTAL
Intervention: TAK-385 (320/80 mg loading/maintenance)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TAK-385 (various doses)
Number of subjects: 43
Study: 29087256

Group type: EXPERIMENTAL
Intervention: Cell phone ownership and stability
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cell phone instability
Number of subjects: 121
Study: 25595923

Group type: EXPERIMENTAL
Intervention: Adjuvant bilateral radiofrequency pulmonary vein ablation (group A)
Number of subjects: 175

Group type: COMPARATOR
Intervention: CABG alone (group B)
Number of subjects: 175
Study: 23794569

Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 21729277

Group type: EXPERIMENTAL
Intervention: Complex oral health care (OHC) intervention
Number of subjects: 0
Study: 19656355

Group type: EXPERIMENTAL
Intervention: EMLA (anesthetic)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 28
Study: 17484298

Group type: EXPERIMENTAL
Intervention: Weighted zero-inflated Poisson model (W-ZIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logistic regression (LR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survival analysis
Number of subjects: 0
Study: 15612857

Group type: EXPERIMENTAL
Intervention: Forgiveness therapy (FT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alternative individual treatment based on routine drug and alcohol therapy topics
Number of subjects: 14
Study: 11726414

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 56
Study: 9394699

Group type: EXPERIMENTAL
Intervention: 90 g cooked field bean flour/d (groups B and C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90 g raw field bean flour/d (group D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 90 g control flour/d (group A)
Number of subjects: 40
Study: 7696825

Group type: COMPARATOR
Intervention: Pamidronate (time-release preparation)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pamidronate (standard tablet preparation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Discontinuation of pamidronate and use of antacid medication
Number of subjects: 49